Fundraising Fox

Akari Therapeutics

NASDAQ: AKTX

Tampa, US · Incorporated in United Kingdom · 15 employees on LinkedIn · 1 known investors

Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates (ADCs) built on a proprietary PH1 spliceosome-modulating payload that disrupts RNA splicing in cancer cells. Its pipeline includes AKTX-101, targeting the Trop2 receptor, and AKTX-102, targeting CEACAM5 across solid tumors.

BiotechDeep TechHealthtech

Founders & leadership

KF
Kameel FaragInterim Chief Financial Officer
AGAbizer Gaslightwala
Abizer GaslightwalaPresident and Chief Executive Officer
GR
Gur RoshwalbExecutive
CR
Clive RichardsonExecutive
DE
Dov ElefantExecutive
RP
Ray PrudoNamed on SEC filing

Board

SP
Samir PatelBoard director
SP
Sandip PatelBoard director
HH
Hoyoung HuhBoard director
RB
Rob BazemoreBoard director
JN
Jim NealBoard director
SU
Stuart UngarBoard director

Investors · 1

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Reported raises · per SEC filings

Form D private placements

$126.3M disclosed across 9 rounds · 2015–2026

▶$1.8MraisedJun 2026 · 6 investors · Other Health Care
Rule 506(b)
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunityfinance.yahoo.com · Jul 2026Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestonesglobenewswire.com · Jun 2026 · press release
Officers, directors & promoters on the filing
  • Ray PrudoDirector
  • Rob BazemoreDirector
  • Hoyoung HuhDirector
  • Samir PatelDirector
  • Sandip PatelDirector
  • Abizer GaslightwalaExecutive Officer, Director
  • Kameel FaragExecutive Officer
  • Jim NealDirector
Offering amount
$5.5M
Amount sold
$1.8M
Sales commissions
$125K
Placement agents
Paulson Investment Company, LLC
First sale
May 2026
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.3MraisedOct 2025 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Samir PatelDirector
  • Sandip PatelDirector
  • Ray PrudoDirector
  • Hoyoung HuhDirector
  • Kameel FaragExecutive Officer
  • Rob BazemoreDirector
  • Abizer GaslightwalaExecutive Officer, Director
  • Jim NealDirector
Offering amount
$6.3M
Amount sold
$6.3M
Sales commissions
$180K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Oct 2025
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJan 2024 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Wendy DiCiccoExecutive Officer
  • Dr. Ray PrudoDirector
  • Rachelle JacquesDirector, Executive Officer
  • Wa'el HashadDirector
  • Michael GrissingerDirector
  • Samir PatelDirector
  • Donald WilliamsDirector
Offering amount
$2M
Amount sold
$2M
Sales commissions
$100K
Placement agents
Paulson Investment Company LLC
First sale
Dec 2023
Incorporated
Other, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2023 · 11 investors · Other Health Care
Rule 506(c)
Officers, directors & promoters on the filing
  • Donald WilliamsDirector
  • Wendy DiCiccoExecutive Officer
  • Michael GrissingerDirector
  • Rachelle JacquesExecutive Officer, Director
  • Wa'el HashadDirector
  • Dr. Ray PrudoDirector
Offering amount
$2M
Amount sold
$2M
Sales commissions
$149.6K
Placement agents
PAULSON INVESTMENT COMPANY LLC
First sale
Oct 2023
Incorporated
Other, United Kingdom
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$12.8MraisedSep 2022 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael GrissingerDirector
  • Melissa Bradford-KlugExecutive Officer
  • Donald WilliamsDirector
  • Torsten HombeckExecutive Officer
  • Ray PrudoDirector
  • Rachelle JacquesExecutive Officer, Director
  • Stuart UngarDirector
  • James HillDirector
  • Miles NunnExecutive Officer
  • David ByrneDirector
Offering amount
$12.8M
Amount sold
$12.8M
Sales commissions
$898.5K
Placement agents
A.G.P./Alliance Global Partners
First sale
Sep 2022
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.3MraisedJul 2021 · 62 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael GrissingerDirector
  • Stuart UngarDirector
  • Peter FeldschreiberDirector
  • David ByrneDirector
  • Ray PrudoDirector
  • Donald WilliamsDirector
  • James HillDirector
  • Clive RichardsonExecutive Officer, Director
Offering amount
$12.3M
Amount sold
$12.3M
Sales commissions
$933K
Placement agents
Paulson Investment Company, LLC
First sale
Jul 2021
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.6MraisedMar 2020 · 53 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart UngarDirector
  • David ByrneDirector
  • Donald WilliamsDirector
  • Michael GrissingerDirector
  • Clive RichardsonExecutive Officer, Director
  • Peter FeldschreiberDirector
  • Ray PrudoDirector
  • James HillDirector
Offering amount
$9.6M
Amount sold
$9.6M
Sales commissions
$764.4K
Placement agents
Paulson Investment Company, LLC
First sale
Feb 2020
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedJul 2019 · 45 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Clive RichardsonExecutive Officer, Director
  • Dov ElefantExecutive Officer, Director
  • Ray PrudoExecutive Officer, Director
  • James HillDirector
  • Stuart UngarDirector
  • David ByrneDirector
  • Donald WilliamsDirector
  • Peter FeldschreiberDirector
  • Michael GrissingerDirector
Offering amount
$4.5M
Amount sold
$4.5M
Sales commissions
$337.5K
Placement agents
Paulson Investment Company, LLC
First sale
Jun 2019
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Robinhood19 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St18 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Seeking Alpha16 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView16 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwits13 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.

Companies competing with Akari Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunityfinance.yahoo.com · Jul 2026Akari Therapeutics Completes Consolidated PIPE Closing, Receives $8.3 Million in Total Q2 2026 Capital | Quiver Quantitativequiverquant.com · Jun 2026Akari Therapeutics completes $8.3m capital raise in Q2 By Investing.cominvesting.com · Jun 2026Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestonesglobenewswire.com · Jun 2026 · press release

Frequently asked questions

What does Akari Therapeutics do?
Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates (ADCs) built on a proprietary PH1 spliceosome-modulating payload that disrupts RNA splicing in cancer cells. Its pipeline includes AKTX-101, targeting the Trop2 receptor, and AKTX-102, targeting CEACAM5 across solid tumors.
Who are Akari Therapeutics's investors?
Akari Therapeutics's investors include New Enterprise Associates (NEA).
How much funding has Akari Therapeutics raised?
Akari Therapeutics has disclosed $126.3M raised across 9 rounds.
Where is Akari Therapeutics headquartered?
Akari Therapeutics is headquartered in Tampa, US.